Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $49.57 Consensus PT from Analysts

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has earned an average recommendation of “Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages […]

Leave a Reply

Your email address will not be published.

Previous post Birkenstock (BIRK) Projected to Post Quarterly Earnings on Thursday
Next post Brokerages Set Helmerich & Payne, Inc. (NYSE:HP) Target Price at $31.78